
As an Amazon Associate and affiliate partner, Menrva Books earns from qualifying purchases. Learn more
Key questions involved in the treatment of disseminated breast cancer are discussed in this well-presented overview. It is the result of an initiative taken by the Swiss Group for Clinical Cancer Research to reveal the most recent developments in experimental and clinical research. The topics discussed include: the comparison of in vitro cultures of epithelial cells with breast cancer cells, the effect of steroids and their antagonists, the involvement of suppressor genes in tumour progression, the modulation of transforming growth factors by estrogen, and prognostic factors such as cERB-2 and EGF-R in breast cancer.
This overview examines critical questions in the treatment of disseminated breast cancer, synthesizing recent experimental and clinical research. The book stems from an initiative by the Swiss Group for Clinical Cancer Research, presenting a comprehensive look at the latest developments. It delves into topics such as comparing in vitro epithelial cell cultures with breast cancer cells, the impact of steroids and their antagonists, the role of suppressor genes in tumor progression, and how estrogen modulates transforming growth factors. Additionally, it explores prognostic factors like cERB-2 and EGF-R.
This work is presented as a well-structured overview of key questions in disseminated breast cancer treatment, reflecting recent advancements from a Swiss research initiative. The scope covers cellular and molecular aspects of cancer progression, including gene regulation and growth factor interactions, alongside clinical prognostic indicators. The material suggests a text aimed at researchers and clinicians seeking detailed insights into experimental and clinical findings. It provides a focused examination of specific biological mechanisms and their therapeutic implications.
Page Count:
92
Publication Date:
1989-01-01
Publisher:
Springer-Verlag
ISBN-10:
0387504567
ISBN-13:
9780387504568
No comments yet. Be the first to share your thoughts!